Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study

References

• Macklon NS, Stouffer RL, Giudice LC, et al. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170–207.
   PubMed Web of Science ®Google Scholar
• Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80:1444–1449.
   PubMed Web of Science ®Google Scholar
• Reichman DE, Zakarin L, Chao K, et al. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 2014;102:99–102.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104:62–70.e3.
   PubMed Web of Science ®Google Scholar
• Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod. 2011;26:2593–2597.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Purata J, Lee J, Whitehouse M, et al. Reproductive outcome is optimized by genomic embryo screening, vitrification, and subsequent transfer into a prepared synchronous endometrium. J Assist Reprod Genet. 2016;33:401–412.
   PubMed Web of Science ®Google Scholar
• Soules MR, Steiner RA, Clifton DK, et al. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab. 1984;58:378–383.
   PubMed Web of Science ®Google Scholar
• Massin NN. stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23:211–220.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101:105–111.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore). 2015;94:e909.
   PubMed Web of Science ®Google Scholar
• Zhu X, Ye H, Fu Y. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertil Steril. 2017;107:379–386.e4.
   PubMed Web of Science ®Google Scholar
• Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steril. 2017;108:505–512.e2.
   PubMed Web of Science ®Google Scholar
• Phillips A, Hahn DW, Klimek S, et al. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception. 1987;36:181–192.
   PubMed Web of Science ®Google Scholar
• Martinez F, Rodriguez-Barredo D, Rodriguez-Purata J, et al. Acceptability and results of corifollitropin alfa (FSH-CFT) and desogestrel (DSG) for ovarian stimulation (COH) in oocyte donors (OD). Fertil Steril. 2017;108:e232.
   Web of Science ®Google Scholar
• Martínez F, Clua E, Santmartí P, et al. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors. Fertil Steril. 2010;94:2433–2436.
   PubMed Web of Science ®Google Scholar
• Pérez-Calvo A, Martínez F, Blockeel C, et al. Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors. Reprod Biomed Online. 2017;35:425–431.
   PubMed Web of Science ®Google Scholar
• Solé M, Santaló J, Boada M, et al. How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes. Hum Reprod. 2013;28:2087–2092.
   PubMed Web of Science ®Google Scholar
• Conti M, Hsieh M, Zamah AM, et al. Novel signaling mechanisms in the ovary during oocyte maturation and ovulation. Mol Cell Endocrinol. 2012;356:65–73.
   PubMed Web of Science ®Google Scholar
• Shoham Z, Schacter M, Loumaye E, et al. The luteinizing hormone surge-the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril. 1995;64:237–251.
   PubMed Web of Science ®Google Scholar
• Giordano JO, Fricke PM, Guenther JN, et al. Effect of progesterone on magnitude of the luteinizing hormone surge induced by two different doses of gonadotropin-releasing hormone in lactating dairy cows. J Dairy Sci. 2012;95:3781–3793.
   PubMed Web of Science ®Google Scholar
• Richter TA, Robinson JE, Lozano JM, et al. Progesterone can block the preovulatory gonadotropin-releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestradiol-responsive cells within the hypothalamus. J Neuroendocrinol. 2005;17:161–169.
   PubMed Web of Science ®Google Scholar
• Cédrin-Durnerin I, Bständig B, Parneix I, et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–116.
   PubMed Web of Science ®Google Scholar
• Obruca A, Korver T, Huber J, et al. Ovarian function during and after treatment with the new progestagen Org 30659. Fertil Steril. 2001;76:108–115.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Zikopoulos K, Schiettecatte J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–2496.
   PubMed Web of Science ®Google Scholar
• Blockeel C, Drakopoulos P, Santos-Ribeiro S, et al. A fresh look at the freeze-all protocol: a SWOT analysis. Hum Reprod. 2016;31:491–497.
   PubMed Web of Science ®Google Scholar
• Drakopoulos P, Blockeel C, Stoop D, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31:370–376.
   PubMed Web of Science ®Google Scholar
• Devesa M, Tur R, Rodríguez I, et al. Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women ≥38 years old. Hum Reprod. 2018;33:2010–2017.
   PubMed Web of Science ®Google Scholar
• Polyzos NP, Drakopoulos P, Parra J, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women. Fertil Steril. 2018;110:661–670.e1.
   PubMed Web of Science ®Google Scholar
• Vanni VS, Somigliana E, Reschini M, et al. Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF/ICSI cycles. PLoS One. 2017;12:e0176482.
   PubMed Web of Science ®Google Scholar
• Borman SM, Chaffin CL, Schwinof KM, et al. Progesterone promotes oocyte maturation, but not ovulation, in nonhuman primate follicles without a gonadotropin surge. Biol Reprod. 2004;71:366–373.
   PubMed Web of Science ®Google Scholar
• Huang B, Ren X, Wu L, et al. Elevated progesterone levels on the day of oocyte maturation may affect top quality embryo IVF cycles. PLoS One. 2016;11:e0145895.
   PubMed Web of Science ®Google Scholar
• Racca A, Santos-Ribeiro S, De Munck N, et al. Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: is there a deleterious effect on embryo quality? Hum Reprod. 2018;33:860–868.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang Y, Lyu Q, et al. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril. 2015;103:1194–1201.e2.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Q, Wang N, et al. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine (Baltimore). 2016;95:e2939.
   PubMed Web of Science ®Google Scholar
• Yu S, Long H, Chang HN, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum. Reprod. 2018;33:229–237.
   PubMed Web of Science ®Google Scholar